Valeant Pharmaceuticals International’s (VRX) “Neutral” Rating Reiterated at BTIG Research

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “neutral” rating reiterated by analysts at BTIG Research in a research report issued on Wednesday.

A number of other brokerages have also recently commented on VRX. Mizuho reiterated an “underperform” rating and issued a $11.00 target price on shares of Valeant Pharmaceuticals International in a research report on Tuesday. Canaccord Genuity restated a “hold” rating and issued a $33.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Thursday, November 3rd. Deutsche Bank AG initiated coverage on shares of Valeant Pharmaceuticals International in a research report on Tuesday, September 20th. They issued a “hold” rating and a $30.00 price objective on the stock. Guggenheim restated a “positive” rating and issued a $55.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Tuesday, November 8th. Finally, Wells Fargo & Company restated a “sell” rating and issued a $19.50 price objective on shares of Valeant Pharmaceuticals International in a research report on Sunday, September 18th. Five research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and six have issued a buy rating to the stock. Valeant Pharmaceuticals International presently has an average rating of “Hold” and a consensus target price of $34.80.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded down 5.6329% during mid-day trading on Wednesday, reaching $15.4762. 25,032,079 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $15.26 and a 200-day moving average price of $21.79. Valeant Pharmaceuticals International has a one year low of $13.00 and a one year high of $101.40. The stock’s market cap is $5.38 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last issued its earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 EPS for the quarter, missing analysts’ consensus estimates of $1.78 by $0.23. The business earned $2.48 billion during the quarter, compared to analysts’ expectations of $2.49 billion. Valeant Pharmaceuticals International had a positive return on equity of 43.81% and a negative net margin of 22.17%. Valeant Pharmaceuticals International’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.74 EPS. On average, analysts predict that Valeant Pharmaceuticals International will post $5.44 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals International’s (VRX) “Neutral” Rating Reiterated at BTIG Research” was originally published by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/valeant-pharmaceuticals-internationals-vrx-neutral-rating-reiterated-at-btig-research/345535.html.

In other news, Director Thomas W. Sr. Ross acquired 5,000 shares of Valeant Pharmaceuticals International stock in a transaction dated Wednesday, December 14th. The stock was purchased at an average cost of $14.73 per share, with a total value of $73,650.00. Following the completion of the purchase, the director now directly owns 26,822 shares in the company, valued at approximately $395,088.06. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Pershing Square Capital Manage sold 3,476,690 shares of the stock in a transaction on Monday, December 12th. The stock was sold at an average price of $14.85, for a total transaction of $51,628,846.50. The disclosure for this sale can be found here. Company insiders own 16.37% of the company’s stock.

Several hedge funds have recently made changes to their positions in VRX. Granite Point Capital Management L.P. purchased a new stake in shares of Valeant Pharmaceuticals International during the second quarter worth about $1,309,000. Convector Capital Management LP boosted its stake in shares of Valeant Pharmaceuticals International by 53.6% in the second quarter. Convector Capital Management LP now owns 192,000 shares of the specialty pharmaceutical company’s stock worth $3,867,000 after buying an additional 67,000 shares during the period. Commerzbank Aktiengesellschaft FI boosted its stake in shares of Valeant Pharmaceuticals International by 15.0% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 231,752 shares of the specialty pharmaceutical company’s stock worth $4,667,000 after buying an additional 30,207 shares during the period. Tocqueville Asset Management L.P. boosted its stake in shares of Valeant Pharmaceuticals International by 27.4% in the second quarter. Tocqueville Asset Management L.P. now owns 51,519 shares of the specialty pharmaceutical company’s stock worth $1,038,000 after buying an additional 11,095 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 0.3% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 472,667 shares of the specialty pharmaceutical company’s stock worth $9,487,000 after buying an additional 1,592 shares during the period. 64.95% of the stock is owned by hedge funds and other institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with our FREE daily email newsletter.

 

Latest News

Orioles Talking Contract with Slugger Jose Bautista
Orioles Talking Contract with Slugger Jose Bautista
Criticism During World Series Humorous to Joe Maddon
Criticism During World Series Humorous to Joe Maddon
Los Angeles Dodgers Awaiting Decision by Twins on Brian Dozier
Los Angeles Dodgers Awaiting Decision by Twins on Brian Dozier
Manny Ramirez Returning to Play Baseball in Japan
Manny Ramirez Returning to Play Baseball in Japan
Rajai Davis Anxious to Start Second Stint With Oakland
Rajai Davis Anxious to Start Second Stint With Oakland
Offseason Moves, Rumors and Possible Deals
Offseason Moves, Rumors and Possible Deals


Leave a Reply

 
© 2006-2017 BBNS.